Cancer drug Xeloda linked to severe skin reactions, official reports

A drug used to treat advanced breast and colorectal cancers has been linked to sometimes fatal skin reactions in patients, its Swiss manufacturer and Canadian health officials said Wednesday.

Xeloda, which treats advanced cancer after complete surgical removal, can cause "severe skin reactions," Health Canada said in a statement.

It said patients had reported severe , such as the life-threatening known as Stevens-Johnson Syndrome or toxic epidermal necrolysis.

The signs and symptoms of this hypersensitivity include flu-like symptoms, fever, itchy skin, mouth sores, as well as painful, red or purplish skin rash that spreads and blisters, causing the top of the skin to shed, along with eye burning, itching and discharge.

Health Canada urged patients using Xeloda to contact their physician "immediately" after experiencing any of those signs or symptoms, so that they may report these to Roche or Health Canada.

Following requests from Canadian health authorities, Hoffmann-La Roche said it will be working with Health Canada to update the drug's prescribing information document.

It has sent a letter to healthcare professionals warning of the "risk of severe cutaneous reactions associated with the use of Xeloda," though it stressed that those cases were "very rare."

add to favorites email to friend print save as pdf

Related Stories

FDA warns of rare skin reactions to acetaminophen

Aug 02, 2013

(HealthDay)—The widely used painkiller acetaminophen, best known as Tylenol, can cause rare but serious skin reactions and a warning about this danger will be added to product labels, the U.S. Food and ...

Temporary tattoos may leave permanent damage

Mar 26, 2013

(HealthDay)—As thousands of college students head to sunny spots for spring break, getting temporary tattoos may seem like a fun thing to do. But the U.S. Food and Drug Administration warns that they can ...

EU regulator: No more problems with Roche drugs

Nov 19, 2013

The European Medicines Agency says it has finished an investigation of the way pharmaceutical giant Roche reported side effects for 19 drugs in the U.S. and has found no new safety concerns.

Recommended for you

70-gene signature not cost-effective in breast cancer

Oct 18, 2014

(HealthDay)—For patients with node-negative breast cancer (NNBC), the 70-gene signature is unlikely to be cost-effective for guiding adjuvant chemotherapy decision making, according to a study published ...

User comments